Clinical findings and treatments of granular corneal dystrophy type 2 (Avellino corneal dystrophy): A review of the literature

Kyung Eun Han, Tae Im Kim, Woo Suk Chung, Seung Il Choi, Bong Yoon Kim, Eung Kweon Kim

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Objectives: To review the literature about clinical findings and treatments of granular corneal dystrophy type 2 (GCD2). Methods: Various literatures on clinical findings, exacerbations after refractive corneal surgery, and treatment modalities of GCD2 were reviewed. Results: GCD2 is an autosomal dominant disease. Mutation of transforming growth factor β-induced gene, TGFBI, or keratoepithelin gene in human chromosome 5 (5q31) is the key pathogenic process in patient with GCD2. Corneal trauma activates TGFBI and then it overproduces transforming growth factor β-induced gene protein (TGFBIp), which is main component of the corneal opacity. Refractive corneal surgery is a popular procedure to correct refractive error worldwide. However, several cases about exacerbation of GCD2 after corneal refractive surgery such as photorefractive keratectomy, laser in situ keratomileusis, and laser epithelial keratomileusis have been reported. The opacities deteriorate patient's best-corrected visual acuity. Recurrence-free interval varies many factors such as the type of procedure the patient had received and the genotype of the patient. To treat the opacities in GCD2, phototherapeutic keratectomy, lamellar keratoplasty, deep lamellar keratoplasty, and penetrating keratoplasty (PKP) were used. However, the recurrence is still an unsolved problem. Conclusions: Perfect treatment of exacerbation after corneal surface ablation does not exist until now. To prevent exacerbation, refractive surgeons must do a careful preoperative examination of candidates in refractive surgeries.

Original languageEnglish
Pages (from-to)296-299
Number of pages4
JournalEye and Contact Lens
Volume36
Issue number5
DOIs
Publication statusPublished - 2010 Sep 1

Fingerprint

Refractive Surgical Procedures
Corneal Transplantation
Transforming Growth Factors
Therapeutics
Photorefractive Keratectomy
Corneal Opacity
Recurrence
Laser In Situ Keratomileusis
Penetrating Keratoplasty
Chromosomes, Human, Pair 5
Refractive Errors
Human Chromosomes
Genes
Visual Acuity
Corneal dystrophy Avellino type
Lasers
Genotype
Mutation
Proteins

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

@article{4aa4f324ad98400381f6f9b5281d21d0,
title = "Clinical findings and treatments of granular corneal dystrophy type 2 (Avellino corneal dystrophy): A review of the literature",
abstract = "Objectives: To review the literature about clinical findings and treatments of granular corneal dystrophy type 2 (GCD2). Methods: Various literatures on clinical findings, exacerbations after refractive corneal surgery, and treatment modalities of GCD2 were reviewed. Results: GCD2 is an autosomal dominant disease. Mutation of transforming growth factor β-induced gene, TGFBI, or keratoepithelin gene in human chromosome 5 (5q31) is the key pathogenic process in patient with GCD2. Corneal trauma activates TGFBI and then it overproduces transforming growth factor β-induced gene protein (TGFBIp), which is main component of the corneal opacity. Refractive corneal surgery is a popular procedure to correct refractive error worldwide. However, several cases about exacerbation of GCD2 after corneal refractive surgery such as photorefractive keratectomy, laser in situ keratomileusis, and laser epithelial keratomileusis have been reported. The opacities deteriorate patient's best-corrected visual acuity. Recurrence-free interval varies many factors such as the type of procedure the patient had received and the genotype of the patient. To treat the opacities in GCD2, phototherapeutic keratectomy, lamellar keratoplasty, deep lamellar keratoplasty, and penetrating keratoplasty (PKP) were used. However, the recurrence is still an unsolved problem. Conclusions: Perfect treatment of exacerbation after corneal surface ablation does not exist until now. To prevent exacerbation, refractive surgeons must do a careful preoperative examination of candidates in refractive surgeries.",
author = "Han, {Kyung Eun} and Kim, {Tae Im} and Chung, {Woo Suk} and Choi, {Seung Il} and Kim, {Bong Yoon} and Kim, {Eung Kweon}",
year = "2010",
month = "9",
day = "1",
doi = "10.1097/ICL.0b013e3181ef0da0",
language = "English",
volume = "36",
pages = "296--299",
journal = "Eye and Contact Lens",
issn = "1542-2321",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

Clinical findings and treatments of granular corneal dystrophy type 2 (Avellino corneal dystrophy) : A review of the literature. / Han, Kyung Eun; Kim, Tae Im; Chung, Woo Suk; Choi, Seung Il; Kim, Bong Yoon; Kim, Eung Kweon.

In: Eye and Contact Lens, Vol. 36, No. 5, 01.09.2010, p. 296-299.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Clinical findings and treatments of granular corneal dystrophy type 2 (Avellino corneal dystrophy)

T2 - A review of the literature

AU - Han, Kyung Eun

AU - Kim, Tae Im

AU - Chung, Woo Suk

AU - Choi, Seung Il

AU - Kim, Bong Yoon

AU - Kim, Eung Kweon

PY - 2010/9/1

Y1 - 2010/9/1

N2 - Objectives: To review the literature about clinical findings and treatments of granular corneal dystrophy type 2 (GCD2). Methods: Various literatures on clinical findings, exacerbations after refractive corneal surgery, and treatment modalities of GCD2 were reviewed. Results: GCD2 is an autosomal dominant disease. Mutation of transforming growth factor β-induced gene, TGFBI, or keratoepithelin gene in human chromosome 5 (5q31) is the key pathogenic process in patient with GCD2. Corneal trauma activates TGFBI and then it overproduces transforming growth factor β-induced gene protein (TGFBIp), which is main component of the corneal opacity. Refractive corneal surgery is a popular procedure to correct refractive error worldwide. However, several cases about exacerbation of GCD2 after corneal refractive surgery such as photorefractive keratectomy, laser in situ keratomileusis, and laser epithelial keratomileusis have been reported. The opacities deteriorate patient's best-corrected visual acuity. Recurrence-free interval varies many factors such as the type of procedure the patient had received and the genotype of the patient. To treat the opacities in GCD2, phototherapeutic keratectomy, lamellar keratoplasty, deep lamellar keratoplasty, and penetrating keratoplasty (PKP) were used. However, the recurrence is still an unsolved problem. Conclusions: Perfect treatment of exacerbation after corneal surface ablation does not exist until now. To prevent exacerbation, refractive surgeons must do a careful preoperative examination of candidates in refractive surgeries.

AB - Objectives: To review the literature about clinical findings and treatments of granular corneal dystrophy type 2 (GCD2). Methods: Various literatures on clinical findings, exacerbations after refractive corneal surgery, and treatment modalities of GCD2 were reviewed. Results: GCD2 is an autosomal dominant disease. Mutation of transforming growth factor β-induced gene, TGFBI, or keratoepithelin gene in human chromosome 5 (5q31) is the key pathogenic process in patient with GCD2. Corneal trauma activates TGFBI and then it overproduces transforming growth factor β-induced gene protein (TGFBIp), which is main component of the corneal opacity. Refractive corneal surgery is a popular procedure to correct refractive error worldwide. However, several cases about exacerbation of GCD2 after corneal refractive surgery such as photorefractive keratectomy, laser in situ keratomileusis, and laser epithelial keratomileusis have been reported. The opacities deteriorate patient's best-corrected visual acuity. Recurrence-free interval varies many factors such as the type of procedure the patient had received and the genotype of the patient. To treat the opacities in GCD2, phototherapeutic keratectomy, lamellar keratoplasty, deep lamellar keratoplasty, and penetrating keratoplasty (PKP) were used. However, the recurrence is still an unsolved problem. Conclusions: Perfect treatment of exacerbation after corneal surface ablation does not exist until now. To prevent exacerbation, refractive surgeons must do a careful preoperative examination of candidates in refractive surgeries.

UR - http://www.scopus.com/inward/record.url?scp=77957588061&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957588061&partnerID=8YFLogxK

U2 - 10.1097/ICL.0b013e3181ef0da0

DO - 10.1097/ICL.0b013e3181ef0da0

M3 - Review article

C2 - 20724852

AN - SCOPUS:77957588061

VL - 36

SP - 296

EP - 299

JO - Eye and Contact Lens

JF - Eye and Contact Lens

SN - 1542-2321

IS - 5

ER -